Stemline Therapeutics, Inc. (NASDAQ: STML) Starts Presentation at 29th Annual Roth Conference
Stemline Therapeutics (NASDAQ: STML) is a clinical-stage biopharmaceutical company that focuses on the discovery, acquisition, development and commercialization of proprietary oncology therapeutics in the United States. It develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in phase II clinical trial for advanced hematologic cancers; SL-701, an immunotherapy to attack tumors that is in phase II clinical trial; and SL-801, a novel oral small molecule reversible inhibitor of nuclear transport, which is in phase I clinical trial for the treatment of solid and hematologic cancers. For more information, visit the company’s website at www.stemline.com. About NetworkNewsWire…